[go: up one dir, main page]

DE3583900D1 - Adrenergische verbindungen. - Google Patents

Adrenergische verbindungen.

Info

Publication number
DE3583900D1
DE3583900D1 DE8585106209T DE3583900T DE3583900D1 DE 3583900 D1 DE3583900 D1 DE 3583900D1 DE 8585106209 T DE8585106209 T DE 8585106209T DE 3583900 T DE3583900 T DE 3583900T DE 3583900 D1 DE3583900 D1 DE 3583900D1
Authority
DE
Germany
Prior art keywords
adrenergic
connections
adrenergic connections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8585106209T
Other languages
English (en)
Inventor
John Francis Debernardis
Fatima Zehra Basha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of DE3583900D1 publication Critical patent/DE3583900D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE8585106209T 1984-06-06 1985-05-21 Adrenergische verbindungen. Expired - Fee Related DE3583900D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61777084A 1984-06-06 1984-06-06

Publications (1)

Publication Number Publication Date
DE3583900D1 true DE3583900D1 (de) 1991-10-02

Family

ID=24474996

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8585106209T Expired - Fee Related DE3583900D1 (de) 1984-06-06 1985-05-21 Adrenergische verbindungen.

Country Status (4)

Country Link
EP (1) EP0166937B1 (de)
JP (1) JPH0635444B2 (de)
CA (1) CA1259995A (de)
DE (1) DE3583900D1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
HK1048259B (en) * 1998-10-20 2005-06-03 Omeros Corporation Irrigation solution and method for inhibition of pain and inflammation
US20030087962A1 (en) 1998-10-20 2003-05-08 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US7973068B2 (en) 1998-10-20 2011-07-05 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
FR2787451B1 (fr) * 1998-12-18 2001-01-26 Adir Nouveaux composes imidazoliniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
AU2003208913A1 (en) * 2002-01-30 2003-09-02 Entremed, Inc. Non-steroidal analogs of 2-methoxyestradiol
AU2004275693A1 (en) 2003-05-28 2005-04-07 Entremed, Inc. Antiangiogenic agents
JP4527379B2 (ja) * 2003-10-17 2010-08-18 田辺三菱製薬株式会社 5−ベンジルオキシ−1,2,3,4−テトラヒドロナフタレン誘導体、及びその製造法
WO2005089256A2 (en) 2004-03-12 2005-09-29 Entremed, Inc. Antiangiogenic agents
JP2009524618A (ja) * 2006-01-27 2009-07-02 エフ.ホフマン−ラ ロシュ アーゲー Cns障害の処置における2−イミダゾールの使用
US8399440B2 (en) 2006-03-20 2013-03-19 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
CA2666762C (en) 2006-10-19 2014-12-30 F. Hoffmann-La Roche Ag Aminomethyl-4-imidazoles
CA2668454A1 (en) 2006-11-02 2008-05-08 F. Hoffmann-La Roche Ag Substituted 2-imidazoles
KR101134226B1 (ko) 2006-11-16 2012-04-10 에프. 호프만-라 로슈 아게 치환된 4-이미다졸
JP2010513238A (ja) 2006-12-13 2010-04-30 エフ.ホフマン−ラ ロシュ アーゲー 微量アミン関連受容体(taar)に対するリガンドとしての新規2−イミダゾール
US20080146523A1 (en) 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
EP2114906B1 (de) 2007-02-02 2014-08-06 F. Hoffmann-La Roche AG 2-aminooxazolinverbindungen als taar1-liganden für erkrankungen des zentralen nervensystems
ES2525229T3 (es) 2007-02-15 2014-12-19 F. Hoffmann-La Roche Ag 2-aminooxazolinas como ligandos de TAAR1
EP2173720A2 (de) 2007-07-02 2010-04-14 F. Hoffmann-Roche AG 2-imidazoline mit guter affinität zu trace-amine-associated-rezeptoren (taars)
EP2173719A1 (de) 2007-07-03 2010-04-14 F. Hoffmann-Roche AG 4-imidazoline und ihre verwendung als antidepressiva
CA2694362A1 (en) 2007-07-27 2009-02-05 F. Hoffmann-La Roche Ag 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands
JP5341084B2 (ja) 2007-08-03 2013-11-13 エフ.ホフマン−ラ ロシュ アーゲー Taar1リガンドとしてのピリジンカルボキシアミド及びベンズアミド誘導体
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
AR090557A1 (es) * 2012-04-02 2014-11-19 Orion Corp DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
US9840513B2 (en) * 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
KR102537050B1 (ko) 2016-03-17 2023-05-26 에프. 호프만-라 로슈 아게 Taar의 작용제로서 활성을 갖는 5-에틸-4-메틸-피라졸-3-카복스아미드 유도체

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2948724A (en) * 1958-04-21 1960-08-09 Sahyun Halogenated derivatives of tetrahydro-1-naphthyl cyclic amidines
NL7310741A (nl) * 1973-08-03 1975-02-05 Akzo Nv Nieuwe n-hydroxy-amidine verbindingen.
FR2539415B1 (fr) * 1983-01-14 1985-09-13 Adir Derives de la d-2 imidazoline, leur preparation et leur application en therapeutique
FR2542738A1 (fr) * 1983-03-18 1984-09-21 Synthelabo Indanyl-2 d2-imidazoline, procede pour la preparer, et compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
EP0166937B1 (de) 1991-08-28
CA1259995A (en) 1989-09-26
JPS617245A (ja) 1986-01-13
EP0166937A2 (de) 1986-01-08
JPH0635444B2 (ja) 1994-05-11
EP0166937A3 (en) 1986-01-22

Similar Documents

Publication Publication Date Title
DE3583900D1 (de) Adrenergische verbindungen.
DE3481957D1 (de) Halbleiteranordnung.
DE3583302D1 (de) Halbleiteranordnung.
IT8520087A0 (it) Passante per collegamenti.
FI851114A0 (fi) Lagringsstabila, snabbt soederfallande farmaceutiska aktivaemnespresstycken.
FI850993A0 (fi) Utryckningsfordon, speciellt tankslaeckningsfordon foer flygfaelt.
FI851937A0 (fi) Utryckningsfordon, saerskilt brandbil.
DE3583521D1 (de) Antivirale verbindungen.
FI851505L (fi) Valsanordning, speciellt foer en kalander.
DE3672133D1 (de) Wirksame verbindungen.
DE3584852D1 (de) Antikonvulsive verbindungen.
FI841948A0 (fi) Kanna, speciellt termoskanna.
FI851220A7 (fi) Kapselointi.
DE3582653D1 (de) Halbleiteranordnung.
DE3577009D1 (de) Photochrome verbindungen.
FI852087L (fi) Glidytsbelaeggning foer skida, speciellt terraengskida.
DE3586547D1 (de) Antibakterielle verbindungen.
FI851383A0 (fi) Polyfosfat innehaollande, flytande tvaettmedelskomposition foer tvaettinraettningar.
FI851935A0 (fi) Utryckningsfordon, saosom brandbil.
FI852088A0 (fi) Enhetliga, styva, fristaoende, gasgenomslaeppliga, laogtemperaturbundna sandkornsformar.
FI840878A7 (fi) Ventilations-/vaermevaexlarsystem foer djurskydd, saerskilt broilerhoenshus.
FI851743L (fi) Saekerhetsfoerslutningskork, saerskilt foer flaskor foer farmaceutiskt bruk.
DE3480714D1 (de) Kationische verbindungen.
DE3578424D1 (de) Quino-benzothiazin-antibakterielle verbindungen.
FI843996A0 (fi) Kluvet braensle-element foer kaernreaktor, isynnerhet foer kokvattenreaktor.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee